What's Happening?
Latigo Biotherapeutics, a clinical-stage biopharmaceutical company focused on developing non-opioid pain medications, has appointed Sara M. Bonstein as an independent director on its board and as chairperson of the audit committee. Bonstein, currently
the CFO of Insmed Incorporated, brings over two decades of financial leadership experience in the biotechnology sector. Her appointment is seen as a strategic move to support Latigo's operational growth and its mission to advance a pipeline of non-opioid therapies. Bonstein's extensive background includes roles at OncoSec Medical, Advaxis, Eli Lilly & Company, and Johnson & Johnson, where she has been instrumental in raising capital and enhancing financial controls.
Why It's Important?
The appointment of Sara M. Bonstein is significant for Latigo Biotherapeutics as it seeks to expand its influence in the non-opioid pain management market. Her expertise in financial strategy and corporate governance is expected to bolster Latigo's efforts to reduce opioid dependency through innovative therapies. This move aligns with broader industry trends focusing on non-addictive pain management solutions, which are crucial given the ongoing opioid crisis in the U.S. Bonstein's leadership could enhance Latigo's ability to attract investment and navigate the complex regulatory landscape, ultimately benefiting patients and healthcare providers seeking safer pain management options.
